Basics |
Verona Pharma
Verona Pharma PLC develops drugs for respiratory diseases. Its products mainly include anti-inflammatory agents and bronchodilators.
|
IPO Date: |
April 24, 2017 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$9.19B |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.40 | 2.76%
|
Avg Daily Range (30 D): |
$0.07 | 0.06%
|
Avg Daily Range (90 D): |
$0.43 | 0.45%
|
Institutional Daily Volume |
Avg Daily Volume: |
.45M |
Avg Daily Volume (30 D): |
.91M |
Avg Daily Volume (90 D): |
2.59M |
Trade Size |
Avg Trade Size (Sh.): |
108 |
Avg Trade Size (Sh.) (30 D): |
131 |
Avg Trade Size (Sh.) (90 D): |
169 |
Institutional Trades |
Total Inst.Trades: |
2,392 |
Avg Inst. Trade: |
$3.3M |
Avg Inst. Trade (30 D): |
$4.09M |
Avg Inst. Trade (90 D): |
$5.7M |
Avg Inst. Trade Volume: |
.05M |
Avg Inst. Trades (Per Day): |
4 |
Market Closing Trades |
Avg Closing Trade: |
$2.97M |
Avg Closing Trade (30 D): |
$6.48M |
Avg Closing Trade (90 D): |
$6.09M |
Avg Closing Volume: |
52.46K |
|
|
Financials |
|
TTM |
Q2 2025 |
Q1 2025 |
Basic EPS
|
|
$.02
|
$-.02
|
Diluted EPS
|
|
$.02
|
$-.02
|
Revenue
|
$
|
$ 103.14M
|
$ 76.26M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$
|
$ 11.92M
|
$ -16.32M
|
Operating Income / Loss
|
$
|
$ 13.31M
|
$ -10.32M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$
|
$ 36.6M
|
$ 1.66M
|
PE Ratio
|
|
|
|
|
|
|